Inovio Pharmaceuticals (INO) Q4 2025 earnings summary

Executive summary

• BLA for INO-3107 accepted for FDA review under the Accelerated Approval Program, with a PDUFA target date of October 30, 2026; FDA raised questions about eligibility for accelerated approval, with a meeting pending.

• Commercial preparations for INO-3107 are underway, including resource optimization, go-to-market planning, and building commercial infrastructure.

• Pipeline progress includes partnerships for glioblastoma and rare disease programs, leveraging DNA medicine platform innovations and new clinical collaborations.

• Published positive immunological and long-term clinical data for INO-3107, showing reduced need for surgery in RRP patients.

• Advanced next-generation DNA medicine technologies, including DMAbs and DPROT, with promising clinical and preclinical results.

Financial highlights

• Ended Q4 2025 with $58.5 million in cash, cash equivalents, and short-term investments, down from $94.1 million at end of 2024.

• Q4 2025 net income was $3.8 million, primarily due to a $21.2 million non-cash gain on warrant liability adjustment; full-year 2025 net loss was $84.9 million, or $1.81 per share.

• Operating expenses for 2025 decreased 23% year-over-year to $86.9 million; Q4 2025 operating expenses were $17.5 million, down from $20.5 million in Q4 2024.

• R&D expenses for Q4 and FY2025 were $10.3M and $54.2M, down from $12.9M and $75.6M in 2024.

• Estimated operational net cash burn for Q1 2026 is $22 million.

Outlook and guidance

• Cash runway projected into Q4 2026, excluding potential capital raises.

• Strategic focus remains on advancing INO-3107 toward FDA approval and commercial launch, with pipeline advancement for other candidates contingent on INO-3107 approval and available resources.

• Expectation to deliver INO-3107 to patients pending FDA approval, with potential to become a preferred first-line treatment.